CA 125 and the detection of recurrent ovarian cancer

A reasonably accurate biomarker for a difficult disease

Authors

  • Robert C. Bast Jr MD

    Corresponding author
    1. Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1400 Pressler Street, Unit 1439, Houston, TX 77030
    Search for more papers by this author

  • See commentary on pages 2854–5, this issue.

Abstract

Rising cancer antigen 125 (CA125) levels have been used to detect recurrence of ovarian cancer. A recent study questions the value of this practice, but the clinical trial has significant limitations and discounts the value of early detection to permit treatment of recurrence with novel and conventional agents.

Ancillary